Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
ITIL-306, first CoStAR-TIL in clinical development, anticipated to start clinical trial ITIL-306-202 in 2H 2023…
News
Taysha Gene Therapies Announces $150 Million Private Placement Financing
Financing led by RA Capital Management with participation from new and existing investors Expected net…
Taysha Gene Therapies Announces $150 Million Private Placement Financing
Financing led by RA Capital Management with participation from new and existing investors Expected net…
Fortrea Reports Second Quarter 2023 Results and Provides Full-Year 2023 Guidance
For the three months ended June 30, 2023: Revenues of $793.0 million GAAP net income…
Fortrea Reports Second Quarter 2023 Results and Provides Full-Year 2023 Guidance
For the three months ended June 30, 2023: Revenues of $793.0 million GAAP net income…
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and…
PDS Biotech Announces Submission of Phase 3 Protocol to FDA to Initiate VERSATILE-003 Trial
VERSATILE-003 will evaluate PDS0101 in combination with KEYTRUDA® in recurrent or metastatic HPV16-positive head and…
Trevena Reports Second Quarter 2023 Results and Provides Business Update
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy;…
Trevena Reports Second Quarter 2023 Results and Provides Business Update
Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy;…
Humacyte Second Quarter 2023 Financial Results and Business Update
– Completed Enrollment in Phase 2/3 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line…
Humacyte Second Quarter 2023 Financial Results and Business Update
– Completed Enrollment in Phase 2/3 V005 Trial of HAV™ in Vascular Trauma Repair; Top-Line…
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase…
Roivant Reports Financial Results for the First Quarter Ended June 30, 2023, and Provides Business Update
RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase…
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company…
HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
BOSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company…
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
– Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index – – Publication…
Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates
– Inclusion into the broad-market Russell 3000® Index and small-cap Russell 2000® Index – – Publication…
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization
Business to prioritize high-potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s…
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic Reprioritization
Business to prioritize high-potential agitation market opportunities for BXCL501 in bipolar disorders, schizophrenia, and Alzheimer’s…
RVL Pharmaceuticals plc Reports Second Quarter 2023 Financial Results; Provides Update on Strategic Business Review
— UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers,…